@article{Herych_Yatsyshyn_2014, title={Optimizing Treatment of Patients with Co-Existing Cardiorespiratory Pathology by Administration of Anti-Inflammatory Roflumilast and Cardioprotective Agent Quercetin}, volume={21}, url={https://ifnmujournal.com/gmj/article/view/237}, abstractNote={The article discusses the research findings on the effectiveness and safety of combination treatment with roflumilast and quercetin in aggravated chronic obstructive pulmonary disease (COPD) along with a co-occurring comorbid ischemic heart disease (IHD). Clinical evidence highlights the effect of combination of roflumilast and quercetin as a part of the basic treatment of COPD and conventional treatment of IHD on clinical symptomatology, C-reactive protein levels, and α<sub>2</sub&gt;-macroglobulin in plasma. It was found that a complex therapy leads to a substantial improvement of patients’ clinical condition owing to reduced systemic inflammatory activation and improved immune defense, which decreases incidence of cardiovascular complications.}, number={3}, journal={Galician Medical Journal}, author={Herych, P. R. and Yatsyshyn, R. I.}, year={2014}, month={Sep.}, pages={65-69} }